Problem

Exonic targets a structural bottleneck in drug discovery: biological data are heterogeneous and noisy, while the discovery process remains siloed, secretive, and expensive. Conventional drug development is widely described as a 10–15-year, high-risk process, with a frequently cited average cost of roughly $2.6 billion per approved drug and clinical failure rates near 90%. Exonic’s economic thesis is that faster, more accessible computational design and early experimental triage can reduce wasted research effort before expensive downstream development.

Its clearest use case is precision gene therapy, particularly designing synthetic enhancers—short DNA sequences intended to activate therapeutic genes in a target cell while remaining quiet elsewhere. Exonic’s initial challenge focuses on liver cancer: generate enhancers that are highly active in HepG2 liver-cancer cells but have low activity in K562 and SK-N-SH off-target cell lines, then validate the best designs in the lab.

Product / Service

Exonic Studio is a web-based synthetic-biology engineering platform. It gives users free access to open-source biological AI models as well as Exonic’s own models, then lets them combine, prompt, and chain those models into visual workflows without writing code. Workflows can be shared, forked, and run by other users, with modules spanning DNA design and scoring, protein structure generation, sequence modeling, peptide/chemical representations, and related utilities. The benefit is a common, lower-friction environment for researchers, computational biologists, and non-specialists to prototype biological designs without maintaining bespoke model integrations.

The current delivery model is research-oriented rather than a clinical or therapeutic product. In its public tournament, Exonic’s Malinois model scores 200-base DNA sequences for activity across three cell lines and helps generate candidate enhancers; community members submit alternatives, and up to 100 designs are synthesized and measured in Exonic’s lab. This creates a feedback loop between open AI workflows, crowdsourced ideas, computational ranking, and wet-lab validation, while the company’s terms describe the platform as research-only.

Market

Exonic competes in the overlap of AI drug discovery, bioinformatics software, synthetic-biology engineering, and precision gene-therapy design. Its model is differentiated less by being another closed drug-discovery pipeline than by combining open biological models, no-code workflow composition, public participation, and experimental validation. Broadly adjacent competitors include Insilico Medicine, Isomorphic Labs, and Google DeepMind in AI-enabled drug discovery; Recursion and insitro in integrated computational and wet-lab discovery; and Foldit in crowdsourced, gamified biological design. Emerald Cloud Lab is an adjacent competitor on remote experimental execution rather than on Exonic’s AI workflow layer.

The company has early technical and community traction but limited publicly disclosed commercial traction. YC lists Exonic as an active San Francisco startup founded in 2025, in the Fall 2025 batch, with a three-person team. Exonic reports that its first application produced 63 synthetic enhancers tested in cancer-cell assays, with six outperforming the best-known sequences head-to-head and 62 of 63 exceeding a stated benchmark; it also reports a 2026 model with zero-shot generalization on held-out genomic-expression datasets. PitchBook reports $500,000 raised from Y Combinator and Pioneer Fund, while its current-revenue field is blank, so Exonic should be viewed as an early, research-stage company with no publicly disclosed revenue rather than as a proven commercial platform.